JP2016529312A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016529312A5 JP2016529312A5 JP2016540387A JP2016540387A JP2016529312A5 JP 2016529312 A5 JP2016529312 A5 JP 2016529312A5 JP 2016540387 A JP2016540387 A JP 2016540387A JP 2016540387 A JP2016540387 A JP 2016540387A JP 2016529312 A5 JP2016529312 A5 JP 2016529312A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- carbocyclyl
- heterocyclyl
- alkynyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCC(*(C)C)=C*=C(*)[*@]1*=CC(C(C=**2C(C(CC)=C3C)=O)=C2*3=C)=C1 Chemical compound CCC(*(C)C)=C*=C(*)[*@]1*=CC(C(C=**2C(C(CC)=C3C)=O)=C2*3=C)=C1 0.000 description 4
- CSLJXILIWIMLTL-UHFFFAOYSA-N CC(C)c1c[n](-c(nc2)ncc2N(C)C)nc1 Chemical compound CC(C)c1c[n](-c(nc2)ncc2N(C)C)nc1 CSLJXILIWIMLTL-UHFFFAOYSA-N 0.000 description 1
- ZAZCIHKBUVQXKV-UHFFFAOYSA-N CC(Nc([n](C1=O)nc2)c2-c2c[n](-c3ccccn3)nc2)=C1Cl Chemical compound CC(Nc([n](C1=O)nc2)c2-c2c[n](-c3ccccn3)nc2)=C1Cl ZAZCIHKBUVQXKV-UHFFFAOYSA-N 0.000 description 1
- XCJHHYWFOXAYBC-UHFFFAOYSA-N CC(c1c[n](-c2ccncn2)nc1)=C Chemical compound CC(c1c[n](-c2ccncn2)nc1)=C XCJHHYWFOXAYBC-UHFFFAOYSA-N 0.000 description 1
- VVAMRKQTTRRZBC-LSDHQDQOSA-N CC/C(/[n]1cnc(-c2ccccn2)c1)=C(/NC(c1ccccc1)=C(CC)C1=O)\N1N Chemical compound CC/C(/[n]1cnc(-c2ccccn2)c1)=C(/NC(c1ccccc1)=C(CC)C1=O)\N1N VVAMRKQTTRRZBC-LSDHQDQOSA-N 0.000 description 1
- LPLZTGZNKNRTLL-UHFFFAOYSA-N CCC(C([n]1nc2)=O)=C(C)Nc1c2-[n]1cnc(-c2ccccn2)c1 Chemical compound CCC(C([n]1nc2)=O)=C(C)Nc1c2-[n]1cnc(-c2ccccn2)c1 LPLZTGZNKNRTLL-UHFFFAOYSA-N 0.000 description 1
- UTTNHAMRKOCBMO-UHFFFAOYSA-N CCC(C([n]1nc2)=O)=C(C)Nc1c2-[n]1cnc(-c2cccnc2)c1 Chemical compound CCC(C([n]1nc2)=O)=C(C)Nc1c2-[n]1cnc(-c2cccnc2)c1 UTTNHAMRKOCBMO-UHFFFAOYSA-N 0.000 description 1
- WWYNJDQPWNRJLC-UHFFFAOYSA-N CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2cc(N(C)C)ccn2)nc1 Chemical compound CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2cc(N(C)C)ccn2)nc1 WWYNJDQPWNRJLC-UHFFFAOYSA-N 0.000 description 1
- PQCIOURXCUVAEZ-UHFFFAOYSA-N CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2nccc(Cl)c2)nc1 Chemical compound CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2nccc(Cl)c2)nc1 PQCIOURXCUVAEZ-UHFFFAOYSA-N 0.000 description 1
- RTWAURZQZXFUNZ-UHFFFAOYSA-N CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2nccc(OC)c2)nc1 Chemical compound CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2nccc(OC)c2)nc1 RTWAURZQZXFUNZ-UHFFFAOYSA-N 0.000 description 1
- RMLRQNYPXZAZLZ-UHFFFAOYSA-N CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2ncccn2)nc1 Chemical compound CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2ncccn2)nc1 RMLRQNYPXZAZLZ-UHFFFAOYSA-N 0.000 description 1
- ANRQHYNHPUYMMB-UHFFFAOYSA-N CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1cnc(-c2ccccn2)[nH]1 Chemical compound CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1cnc(-c2ccccn2)[nH]1 ANRQHYNHPUYMMB-UHFFFAOYSA-N 0.000 description 1
- JPEUQZVNSKXPHA-UHFFFAOYSA-N CNc1c[n](-c2nc(N(C)C)ccn2)nc1 Chemical compound CNc1c[n](-c2nc(N(C)C)ccn2)nc1 JPEUQZVNSKXPHA-UHFFFAOYSA-N 0.000 description 1
- ZTDDWLMWLULANI-UHFFFAOYSA-N Cc1ccnc(-[n]2ncc(N)c2)n1 Chemical compound Cc1ccnc(-[n]2ncc(N)c2)n1 ZTDDWLMWLULANI-UHFFFAOYSA-N 0.000 description 1
- XHRMXJNKNQKYRQ-UHFFFAOYSA-N O=C1[n]2ncc(-c3c[n](-c4ccccn4)nc3)c2NC2=C1CCC2 Chemical compound O=C1[n]2ncc(-c3c[n](-c4ccccn4)nc3)c2NC2=C1CCC2 XHRMXJNKNQKYRQ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361874310P | 2013-09-05 | 2013-09-05 | |
| US61/874,310 | 2013-09-05 | ||
| PCT/US2014/054114 WO2015035062A1 (en) | 2013-09-05 | 2014-09-04 | Antiproliferative compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016529312A JP2016529312A (ja) | 2016-09-23 |
| JP2016529312A5 true JP2016529312A5 (enExample) | 2017-09-07 |
| JP6336598B2 JP6336598B2 (ja) | 2018-06-06 |
Family
ID=51541384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540387A Expired - Fee Related JP6336598B2 (ja) | 2013-09-05 | 2014-09-04 | 抗増殖性化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9505767B2 (enExample) |
| EP (1) | EP3041474B1 (enExample) |
| JP (1) | JP6336598B2 (enExample) |
| KR (1) | KR20160049003A (enExample) |
| CN (1) | CN105611933B (enExample) |
| CA (1) | CA2922925A1 (enExample) |
| MX (1) | MX2016002794A (enExample) |
| RU (1) | RU2016112568A (enExample) |
| WO (1) | WO2015035062A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104981458B (zh) | 2012-10-02 | 2017-07-21 | 吉利德科学公司 | 组蛋白去甲基化酶抑制剂 |
| SG10201707027SA (en) | 2013-02-27 | 2017-09-28 | Epitherapeutics Aps | Inhibitors of histone demethylases |
| EP2970307B1 (en) * | 2013-03-13 | 2020-03-11 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
| KR20170040805A (ko) | 2014-08-27 | 2017-04-13 | 길리애드 사이언시즈, 인코포레이티드 | 히스톤 데메틸라제를 억제하기 위한 화합물 및 방법 |
| SG11201702075QA (en) | 2014-10-29 | 2017-04-27 | Dong A St Co Ltd | Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms) |
| WO2016186949A1 (en) * | 2015-05-15 | 2016-11-24 | Whetstine Johnathan R | Methods relating to the prevention and treatment of drug resistance |
| SG11201901747VA (en) | 2016-08-31 | 2019-03-28 | Agios Pharmaceuticals Inc | Inhibitors of cellular metabolic processes |
| US20200048259A1 (en) * | 2016-10-12 | 2020-02-13 | Merck Sharp & Dohme Corp. | Kdm5 inhibitors |
| US10975084B2 (en) | 2016-10-12 | 2021-04-13 | Merck Sharp & Dohme Corp. | KDM5 inhibitors |
| WO2018160356A1 (en) | 2017-02-28 | 2018-09-07 | University Of Massachusetts | Genetic and pharmacological transcriptional upregulation of the repressed fxn gene as a therapeutic strategy for friedreich ataxia |
| CN108947985A (zh) * | 2017-05-22 | 2018-12-07 | 苏州偶领生物医药有限公司 | 用作自噬调节剂的化合物及其制备方法和用途 |
| WO2019040499A2 (en) | 2017-08-21 | 2019-02-28 | Navigen, Inc. | ARF6 INHIBITORS AND ASSOCIATED METHODS |
| MX2020002869A (es) * | 2017-09-15 | 2020-07-24 | Aduro Biotech Inc | Compuestos de pirazolopirimidinona y usos de los mismos. |
| US20220242872A1 (en) * | 2019-06-24 | 2022-08-04 | Dana-Farber Cancer Institute, Inc. | E3 ligase binders and uses thereof |
| US20220289751A1 (en) * | 2019-07-17 | 2022-09-15 | Ono Pharmaceutical Co., Ltd. | Compound having kdm5 inhibitory activity and pharmaceutical use thereof |
| CR20220308A (es) | 2019-11-25 | 2022-08-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso |
| CN116425757B (zh) * | 2022-01-13 | 2025-05-20 | 浙江同源康医药股份有限公司 | 多环类化合物及其用途 |
| JP2025513455A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| CN120187416A (zh) | 2022-11-11 | 2025-06-20 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的组合疗法 |
| WO2025194015A1 (en) * | 2024-03-15 | 2025-09-18 | Dem Biopharma, Inc. | Heteroaryl modulators of gpr84 and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| AU639726B2 (en) | 1989-09-08 | 1993-08-05 | Duke University | Structural alterations of the egf receptor gene in human gliomas |
| US5356897A (en) * | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| EP0659439B1 (en) | 1993-12-24 | 2001-10-24 | MERCK PATENT GmbH | Immunoconjugates |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| CN1068323C (zh) | 1994-07-21 | 2001-07-11 | 阿克佐诺贝尔公司 | 环酮过氧化物配制剂 |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE69522717T2 (de) | 1995-03-30 | 2002-02-14 | Pfizer Inc., New York | Chinazolinderivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| EP0831880A4 (en) | 1995-06-07 | 2004-12-01 | Imclone Systems Inc | ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH |
| ATE212993T1 (de) | 1995-07-06 | 2002-02-15 | Novartis Erfind Verwalt Gmbh | Pyrolopyrimidine und verfahren zu ihrer herstellung |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| HU228446B1 (en) | 1996-04-12 | 2013-03-28 | Warner Lambert Co | Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof |
| JP4386967B2 (ja) | 1996-07-13 | 2009-12-16 | グラクソ、グループ、リミテッド | プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物 |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| EP0980244B1 (en) | 1997-05-06 | 2003-06-04 | Wyeth Holdings Corporation | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| KR20010031813A (ko) | 1997-11-06 | 2001-04-16 | 윌리암 에이취 캘넌, 에곤 이 버그 | 결장 폴립 치료용 티로신 키나제 억제제로서의 퀴나졸린유도체의 용도 |
| EP1131304B1 (en) | 1998-11-19 | 2002-12-04 | Warner-Lambert Company | N- 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
| TWI271406B (en) | 1999-12-13 | 2007-01-21 | Eisai Co Ltd | Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same |
| JP4100865B2 (ja) * | 1999-12-13 | 2008-06-11 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 三環式縮合異項環化合物、その製造法およびその医薬 |
| AU2003240488A1 (en) | 2002-06-04 | 2003-12-19 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents |
| US7605155B2 (en) * | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| ES2559679T3 (es) * | 2006-06-20 | 2016-02-15 | Abbvie Inc. | Pirazoloquinazolinonas como inhibidores de PARP |
| WO2010086040A1 (en) | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy |
| CN101906105B (zh) * | 2009-06-08 | 2013-01-16 | 河北医科大学 | 吡唑并[1，5-a]嘧啶酮衍生物及其药物组合物以及其用途 |
| WO2012149157A2 (en) * | 2011-04-26 | 2012-11-01 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| WO2014066795A1 (en) | 2012-10-25 | 2014-05-01 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| ES2635016T3 (es) * | 2013-03-01 | 2017-10-02 | Fundación Para La Investigación Médica Aplicada | Nuevos compuestos como inhibidores duales de fosfodiesterasas e histonas deacetilasas |
| EP2970307B1 (en) | 2013-03-13 | 2020-03-11 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
-
2014
- 2014-09-04 US US14/477,566 patent/US9505767B2/en active Active
- 2014-09-04 RU RU2016112568A patent/RU2016112568A/ru not_active Application Discontinuation
- 2014-09-04 WO PCT/US2014/054114 patent/WO2015035062A1/en not_active Ceased
- 2014-09-04 CN CN201480055129.0A patent/CN105611933B/zh active Active
- 2014-09-04 CA CA2922925A patent/CA2922925A1/en not_active Abandoned
- 2014-09-04 KR KR1020167008823A patent/KR20160049003A/ko not_active Withdrawn
- 2014-09-04 EP EP14766355.3A patent/EP3041474B1/en active Active
- 2014-09-04 JP JP2016540387A patent/JP6336598B2/ja not_active Expired - Fee Related
- 2014-09-04 MX MX2016002794A patent/MX2016002794A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016529312A5 (enExample) | ||
| RU2016112568A (ru) | Антипролиферативные соединения | |
| JP2017530984A5 (enExample) | ||
| JP2018505169A5 (enExample) | ||
| Manara et al. | NVP-BEZ235 as a new therapeutic option for sarcomas | |
| ES2694513T3 (es) | Derivado de quinolina | |
| IL275333B2 (en) | Inhibitors of fibroblast activation protein | |
| JP2018510851A5 (enExample) | ||
| TWI690525B (zh) | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 | |
| JP2017528475A5 (enExample) | ||
| JP2016525075A5 (enExample) | ||
| RU2018103944A (ru) | Производные этинила как модуляторы метаботропного рецептора глутамата | |
| JP2018520195A5 (enExample) | ||
| JP2010522194A5 (enExample) | ||
| RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
| JP2016504365A5 (enExample) | ||
| RU2008136188A (ru) | Противораковая фармацевтическая композиция | |
| JP2015531366A5 (enExample) | ||
| RU2016130932A (ru) | Производные хинолона как ингибиторы рецептора фактора роста фибробластов | |
| RU2015116749A (ru) | Антагонисты mglu2/3 для лечения аутических расстройств | |
| RU2013147823A (ru) | (альфа-замещенные аралкиламино-и гетероарилалкиламино)пиримидинил-и 1, 3, 5-триазинилбензимидазолы, их фармацевтические композиции и их применение в лечении пролиферативных заболеваний | |
| KR20150081344A (ko) | 조합 요법 | |
| EP3053578B1 (en) | Combination cancer therapy using azabicyclo compound | |
| de Jonge et al. | Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors | |
| RU2016138676A (ru) | Ингибиторы усилителя zeste гомолога 2 |